Key result
Edoxaban was as effective and safer than warfarin in preventing thromboembolic risk in patients with atrial fibrillation and venous thromboembolism.
Why the study?
Is edoxaban as effective and safe as warfarin in preventing thromboembolic risk in patients with atrial fibrillation and venous thromboembolism?
Is edoxaban as effective and safe as warfarin in preventing thromboembolic risk in patients with atrial fibrillation and venous thromboembolism?
Edoxaban represents a valuable, effective, and safe alternative to warfarin for treating thromboembolic risk in patients with AF and VTE.
May support edoxaban over warfarin in AF/VTE; hypothesis-generating from Level 5 data and needs randomized confirmation.
Oral anticoagulation is the therapeutic cornerstone in preventing thromboembolic risk in both atrial fibrillation (AF) and venous thromboembolism (VTE). After decades of the sole therapeutic oral anticoagulation option being warfarin, the introduction of non-vitamin K antagonist oral anticoagulants has heralded a new era. Edoxaban is the latest addition to these available for clinical use. Edoxaban was as effective and safer than warfarin in preventing thromboembolic risk in AF patients. Similarly, edoxaban effectiveness and safety was evident when treating VTE patients to prevent recurrent VTE or VTE-related death. Therefore, edoxaban represents a valuable alternative in treating thromboembolic risk for AF and VTE patients.
No takes yet. Share an insight, caveat, or question.
Proietti et al. (2016) conducted a review in Atrial fibrillation (AF) and venous thromboembolism (VTE). Edoxaban vs. Warfarin was evaluated on Thromboembolic risk, recurrent VTE, or VTE-related death. Edoxaban was as effective and safer than warfarin in preventing thromboembolic risk in patients with atrial fibrillation and venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: